ExBiome is a cutting-edge RNA diagnostic company that is revolutionizing cancer detection. With a focus on lymphoma, a type of blood cancer, ExBiome is developing its proprietary ExomiR technology platform to detect molecular markers released by tumors and measure how cancers are responding to therapy. By analyzing small genetic molecules present in extracellular vesicles, ExBiome's platform offers a non-invasive approach to monitoring health status.

Starting from a standard blood sample, their innovative approach isolates exosomes, purifies and measures RNA, and interprets the data using advanced algorithms. The aim is to provide clinicians with a simple and cost-effective blood test to track the progress of lymphoma treatment and effectively detect relapse. Backed by a team of biotech entrepreneurs and scientists with expertise in liquid biopsies, ExBiome is at the forefront of advancing diagnostic technology.

Contact ExBiome to learn more about their groundbreaking ExomiR technology platform